Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 161 of 161 results for prostate cancer

  1. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development [GID-TA11199] Expected publication date: TBC

  2. Diabetic foot problems: prevention and management (NG19)

    This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

  3. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  4. Developing NICE guidelines: the manual (PMG20)

    Developing NICE guidelines: the manual

  5. NICE draft guidance recommends apalutamide for treating prostate cancer

    NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults

  6. Artificial intelligence technologies to speed up contouring in radiotherapy treatment planning

    Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers such as lung, prostate or colorectal, NICE has said in draft guidance.

  7. NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance

    Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.

  8. NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals

    Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.

  9. Non-invasive MRI scan for Prostate Cancer recommended by NICE

    NICE has recommended the scan as a first-line investigation for people with suspected clinically localised prostate cancer.

  10. Behind the Headlines - Prostate cancer drug decision a 'cruel twist'

    We take a closer look at media coverage that claims our prostate cancer drug decision is a 'cruel twist' for patients.

  11. Helping GPs make an early diagnosis of cancer

    Thousands of lives in England could be saved each year if the NHS follows updated guidance to help it diagnose cancer earlier. Here we outline what the guidance means for GPs.